Lipid lowering: statins and the future

James Shepherd

Cardiovascular disease (CVD) is the leading cause of death in developed and many developing countries. Between 1970 and 1992 there has been a slow decline in some areas, notably North America, Western Europe, Australia, and New Zealand. However, CVD mortality has recently increased in Eastern and Central Europe.

A whole spectrum of therapeutic tools is available to manage CVD including thrombolytics, antiplatelet drugs, β blockers, angiotensin converting enzyme (ACE) inhibitors, and statins. By using these drugs singly or in combination, CVD risk can be reduced by as much as 50%.

Statin treatment

1987 was a pivotal year for statins. It was the first year that statin treatment became widely available and the first statin, lovastatin, was marketed in the USA. At the same time the first treatment guidelines were released providing recommendations based on the emerging evidence. Moreover, there was the first official recognition of the relation between raised cholesterol concentrations and coronary heart disease risk.

At that time there were sceptics who did not believe that lowering cholesterol would have mortality benefits, and some even suggested that lipid lowering drugs could have fatal side effects. Major clinical trials have dispelled these unfounded theories.

In particular there were five major clinical trials looking at lipid lowering with the new statin drugs: 4S, LIPID, CARE, WOSCOPS, and AFCAPS/TexCAPS (fig 1). These studies showed that whatever cardiovascular risk a patient has (ranging from previous myocardial infarction to low plasma cholesterol), they will benefit from cholesterol reduction using statins.

There are a number of different statins available and more are being developed. Interestingly, all of the drugs in this class are different from each other pharmacologically. These pharmacological differences will influence the way in which these agents perform.

Current situation

Despite the strong evidence highlighting the benefits of lipid lowering, under treatment remains an ongoing problem with only one third of eligible patients receiving treatment.

Meanwhile, vascular disease remains a worldwide challenge. Heart disease is a leading cause of premature death and stroke is the leading cause of long term disability. This presents enormous costs to patients, health care systems, and society. Many at risk patients are currently not identified or treated and therefore are not given the opportunity to benefit from a treatment which has proven efficacy.

ANGIOGRAPHIC TRIALS

The introduction of statins has not only changed the clinical management of patients but has also challenged our understanding of the pathology and treatment of atherosclerotic plaques. Angiographic or ultrasound studies have been designed to demonstrate shrinkage of lesions as a consequence of statin treatment. Results of these trials revealed that all of the drugs produced similar reductions in low density lipoprotein (LDL) cholesterol. There were consistent and significant reductions in clinical events, despite the fact that lesions remained.

The clinical benefit therefore eclipsed the angiographic improvement in lumen diameter.

Although angiographic intervention is important because it relieves symptoms, it may not actually reduce the risk of mortality in the long term as it treats lesions that are symptomatic but that do not necessarily lead to fatal occlusion. The lesion of most importance is the relatively small and asymptomatic plaque that might not be seen by angiography (fig 2). However, because of the presence of large amounts of lipid and poor fibrous architecture, a thin fibrous cap and a high level of inflammation it is more likely to rupture. Ideally, the architecture of the lesion should be changed to have a thick fibrous cap, little inflammation, and with a stable architecture that is criss-crossed with collagen.

It may be that statins are doing more than just changing blood cholesterol concentrations, and are, in fact, changing the whole architecture of the plaque.

Department of Pathological Biochemistry, University of Glasgow, Glasgow Royal Infirmary, Alexander Parade, Glasgow G31 2ER, UK J Shepherd

Correspondence to: Professor Shepherd email: jshepherd@grri-biochem.org

Figure 1 The relevance of landmark statin trials to clinical practice.

Figure 2 Most myocardial infarctions arise from smaller stenoses.
Lipid lowering treatment

followed for five years.9 Received gemfibrozil or placebo and were low HDL, and a slight elevation in triglycerides, deficiency but who had average LDL cholesterol, patients with clear evidence of vascular insufficiency but who had average LDL cholesterol, low HDL, and a slight elevation in triglycerides, received gemfibrozil or placebo and were followed for five years.9

There is ample evidence to support the benefits of cholesterol reduction for all patients. In the last few months data have become available which explore the role of statins in modifying patients’ lipid profiles. In a randomised, double blind, multicentre study, patients with clear evidence of vascular insufficiency but who had average LDL cholesterol, low HDL, and a slight elevation in triglycerides, received gemfibrozil or placebo and were followed for five years.9

The results showed that the patients’ cholesterol concentrations did not change—LDL cholesterol concentrations were identical in the treatment and placebo arms of the study. However, the patients’ HDL concentrations rose in response to treatment and triglyceride concentrations fell but still remained within the normal range (fig 3). Despite these subtle changes there was a 22% benefit in terms of fatal and non-fatal myocardial infarction with no effect at all on cancer rates. Lipid lowering should not be aimed solely at reducing LDL, but also at producing a range of changes including lowering triglycerides and raising HDL.

Finally, the possibility of statin treatment working through a mechanism other than the reduction of cholesterol should be explored.

The future
As the population continues to age, statins will be prescribed more frequently among elderly patients. Polypharmacy and drug interactions will therefore become increasingly important issues. As one of the major pathways for drug detoxification is the cytochrome P450 system in the liver, the ideal statin would have a different metabolic pathway. There are already some statins available and others under development that have these properties.

![Figure 3 Lipid concentrations in response to treatment with gemfibrozil.](http://heart.bmj.com/)

**Trial acronyms**
- CARE: Cholesterol and Recurrent Events Trial
- LIPID: Long Term Intervention with Pravastatin in Ischaemic Disease
- 4S: Scandinavian Simvastatin Survival Study
- TexCAPS: Texas Coronary Atherosclerosis Prevention Study
- WOSCOPS: West of Scotland Coronary Prevention Study